XB-IMG-154781
Xenbase Image ID: 154781
|
Fig. 5. FGF dose response. (A) Stage 10.5 ectoderm was treated with
increasing doses of bFGF (0.08, 0.4, 2, 10, 50, 250, 1250 ng/ml) and
then cultured to the early tailbud stage (stage 20). RT-PCR analysis
of nrp-1, otx2, En-2, Krox 20, Hox B9, Muscle actin, Collagen type
II shows that when stage 10.5 ectoderm is treated with increasing
amounts of bFGF, nrp-1 expression increases. At 2 ng/ml Hox B9
and 10 ng/ml Krox 20 are induced, while En-2 or otx2 is not induced
by any dose, and the low level expression of otx2 seen in untreated
explants is repressed by 0.4 ng/ml or more of bFGF. bFGF treatment
on St 10.5 ectoderm did not induce muscle actin or collagen type II
mesoderm, and repressed XAG-1 expression. EF-1a is a loading
control. (B) When ectoderm is treated at stage 11, En-2 is induced by
a wide range of doses, with 2 ng/ml being the minimal dose. Image published in: Lamb TM and Harland RM (1995) Copyright © 1995. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. Larger Image Printer Friendly View |